Tolerability of mycophenolate sodium in renal transplant recipients
- 9 October 2018
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 40 (6) , 1548-1558
Abstract
Background Kidney transplant recipients (KTR) receive fixed daily doses of mycophenolate sodium as part of the immunosuppressive regimen. Dose reductions occur primarily due to adverse events and may be associated with an increased risk of acute rejection and graft loss. Objectives To evaluate the tolerability of mycophenolate in kidney transplant recipients receiving tacrolimus and prednisone. Setting The study was performed at Hospital do Rim, Federal University of São Paulo in Brazil. Method This was a retrospective cohort study including 506 patients. Tolerability of mycophenolate sodium was classified into the following groups: Temporary reduction (TR), definitive reduction (DR), temporary interruption (TI), permanent discontinuation (PD) and without modification (WM). Main outcome measure The cause of mycophenolate dose change and its influence on rejection-free survival during the first 3 years after transplantation. Results The cumulative incidence of dose change was 51.2% (11%TR, 44%DR, 24%TI, and 21%PD). Gastrointestinal (45.3%), infection (31.9%) and hematological (14.9%) systems accounted for most of the dose changes. The adverse events with higher incidence were diarrhea, cytomegalovirus (CMV) infection and leukopenia. Changes in dose of mycophenole were associated with reduced acute rejection-free survival compared with patients WM group (71.4%TR, 58.9%DR, 56.7%TI, 53.7%PD vs. 74.2%WM, p = 0.020). Only patients with PD showed inferior patient (59.3% vs. 94.4%, p = 0.001) and death-censored graft (83.3% vs. 92.5%, p = 0.074) survivals compared to patients WM. Conclusion In this cohort, changes in the dose of mycophenolate were associated with increased risk of acute rejection and permanent discontinuation was associated with inferior patient and graft survival.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
This publication has 30 references indexed in Scilit:
- Safety and Efficacy of Intensified Versus Standard Dosing Regimens of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant PatientsTransplantation, 2011
- Enteric-coated mycophenolate sodiumExpert Opinion on Drug Safety, 2010
- Mycophenolate Mofetil Versus Enteric-Coated Mycophenolate Sodium: A Large, Single-Center Comparison of Dose Adjustments and Outcomes in Kidney Transplant RecipientsTransplantation, 2010
- Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled TrialTransplantation, 2008
- Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant RecipientsClinical Pharmacokinetics, 2007
- Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co‐administered enteric‐coated mycophenolate sodiumClinical Transplantation, 2005
- Crohn's‐like changes in the colon due to mycophenolate?Colorectal Disease, 2004
- Enteric Coated Mycophenolate Sodium is Therapeutically Equivalent to Mycophenolate Mofetil in de novoRenal Transplant PatientsAmerican Journal of Transplantation, 2004
- Enteric-Coated Mycophenolate Sodium can be Safely Administered in Maintenance Renal Transplant Patients: Results of a 1-Year StudyAmerican Journal of Transplantation, 2004
- Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrheaTransplantation, 2003